Lali Medina-Kauwe, PhD, former co-leader of the Cancer Biology Program in Cedars-Sinai Cancer, has assumed a new role as associate director for Basic Research.
Cedars-Sinai Cancer investigators have created a blood test that uses a technology made commonly available during the COVID-19 pandemic to detect the most common form of liver cancer—at an early enough stage that cure is possible. Their work was published online in the peer-reviewed journal Hepatology.
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in the peer-reviewed journal Cell Reports, could lead to improved treatments for soft-tissue sarcomas.
Marc Botnick, MD, a board-certified radiation oncologist with more than 20 years of experience managing all cancer types, has been named regional medical director for Radiation Oncology at Cedars-Sinai Cancer. His primary clinical practice site will be at Cedars-Sinai Tarzana Radiation Oncology, but he will work closely with physicians throughout the enterprise.
Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy. Their results, published today in the peer-reviewed Journal of the National Cancer Institute, could one day help guide clinicians to the most effective treatments for cancer patients.
Howard Sandler, MD, chair of the Department of Radiation Oncology at Cedars-Sinai Cancer, has been named president-elect of the American Society for Radiation Oncology (ASTRO). Sandler will begin his term as president-elect in October, followed by single-year terms as president, chair and then immediate past chair of the ASTRO Board.
Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Experts from Cedars-Sinai Cancer, ranked among the top 10 in the nation for cancer care, will present novel research and clinical advances throughout the 2022 annual meeting of the American Society of Clinical Oncology (ASCO), taking place in person and virtually June 3-7 in Chicago.
Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy—a commonly used hormone injection—plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. The findings were published in the peer-reviewed journal The Lancet.
Two internationally prominent cancer experts from Cedars-Sinai and USC will train a new generation of investigators to propel scientific advances in cancer through a novel grant from the U.S. Department of Defense.
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Internationally prominent gynecologic oncologist Kenneth H. Kim, MD, recently was selected to direct the Division of Gynecologic Oncology at Cedars-Sinai Cancer. He also serves as chair of the cancer center’s Committee for Oversight of Training and Education.
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators.